Celularity (NASDAQ:CELU – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Risk & Volatility
Celularity has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500.
Valuation & Earnings
This table compares Celularity and Ernexa Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celularity | $18.67 million | 1.63 | -$91.72 million | ($1.69) | -0.56 |
| Ernexa Therapeutics | $580,000.00 | 5.57 | -$14.08 million | ($14.35) | -0.14 |
Ernexa Therapeutics has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
19.0% of Celularity shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Celularity and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celularity | -246.65% | N/A | -48.20% |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
Analyst Ratings
This is a summary of current recommendations and price targets for Celularity and Ernexa Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 1,415.15%. Given Ernexa Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Celularity.
Summary
Ernexa Therapeutics beats Celularity on 9 of the 14 factors compared between the two stocks.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
